Literature DB >> 29434968

Characterization of circulating tumor cells in newly diagnosed breast cancer.

Lu Xu1, Songlin Jia1, Hengyu Li1, Yue Yu1, Guoping Liu1, Yanmei Wu1, Xishui Liu1, Chaoqian Liu1, Yue Zhou2, Zhenzhen Zhang1,2, Yuan Sheng1.   

Abstract

Identification of circulating tumor cells (CTCs) by surface marker expression and ploidy analysis [immunostaining-fluorescence in situ hybridization (iFISH)] has been shown to be a highly sensitive method in the identification of certain solid cancers. In the present study, iFISH analysis was performed to identify CTCs in 184 patients with newly diagnosed non-metastatic breast cancer, and the distribution of CTC subtypes was characterized based on cytokeratin (CK) expression and ploidy status. It was revealed that CTCs of non-metastatic, aneuploid breast cancers, independent of CK expression profile, can be detected with high sensitivity (90.76%) by the iFISH system. Higher CTC counts and sensitivity were observed in patients with increased tumor size burden and unfavorable hormone receptor status. Investigation of CTC subtypes based on ploidy analysis indicated that triploid CTCs constituted the majority of CTCs evaluated. While CK-positive CTCs were detected in a small cohort of patients, an overall low rate of CK expression was observed in the 18 patient samples evaluated. Of note, CK expression was rare in CTCs detected in patients with Herceptin 2 (Her2)-positive or triple-negative [estrogen receptor (ER)-, progesterone receptor (PR)- and Her2-negative], indicating that lack of ER and PR may result in promotion of epithelial-mesenchymal transition and enhancement of tumor aggression.

Entities:  

Keywords:  breast cancer; circulating tumor cell; cytokeratin; hormone receptor status; ploidy analysis; tumor size

Year:  2017        PMID: 29434968      PMCID: PMC5777306          DOI: 10.3892/ol.2017.7540

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  25 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

2.  Role of primary breast cancer characteristics in predicting positive sentinel lymph node biopsy results: a multivariate analysis.

Authors:  Marie Chen; Susan Palleschi; Ali Khoynezhad; Gary Gecelter; Corrado P Marini; H Hank Simms
Journal:  Arch Surg       Date:  2002-05

Review 3.  Circulating tumor cells: liquid biopsy of cancer.

Authors:  Catherine Alix-Panabières; Klaus Pantel
Journal:  Clin Chem       Date:  2012-09-26       Impact factor: 8.327

Review 4.  The different roles of ER subtypes in cancer biology and therapy.

Authors:  Christoforos Thomas; Jan-Åke Gustafsson
Journal:  Nat Rev Cancer       Date:  2011-07-22       Impact factor: 60.716

5.  Diagnostic yield of primary circulating tumor cells in women suspected of breast cancer: the BEST (Breast Early Screening Test) study.

Authors:  Nigel P Murray; Roxana Miranda; Amparo Ruiz; Elsa Droguett
Journal:  Asian Pac J Cancer Prev       Date:  2015

Review 6.  Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.

Authors:  Xiaojiang Cui; Rachel Schiff; Grazia Arpino; C Kent Osborne; Adrian V Lee
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

Review 7.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Authors:  Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

8.  ERalpha signaling through slug regulates E-cadherin and EMT.

Authors:  Y Ye; Y Xiao; W Wang; K Yearsley; J X Gao; B Shetuni; S H Barsky
Journal:  Oncogene       Date:  2010-01-18       Impact factor: 9.867

9.  Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood.

Authors:  Stephen D Mikolajczyk; Lisa S Millar; Pavel Tsinberg; Stephen M Coutts; Maryam Zomorrodi; Tam Pham; Farideh Z Bischoff; Tony J Pircher
Journal:  J Oncol       Date:  2011-04-19       Impact factor: 4.375

10.  Circulating tumor cells in newly diagnosed inflammatory breast cancer.

Authors:  Michal Mego; Antonio Giordano; Ugo De Giorgi; Hiroko Masuda; Limin Hsu; Mario Giuliano; Tamer M Fouad; Shaheenah Dawood; Naoto T Ueno; Vicente Valero; Eleni Andreopoulou; Ricardo H Alvarez; Wendy A Woodward; Gabriel N Hortobagyi; Massimo Cristofanilli; James M Reuben
Journal:  Breast Cancer Res       Date:  2015-01-09       Impact factor: 6.466

View more
  8 in total

1.  Circulating tumor cells are associated with poor outcomes in early-stage hepatocellular carcinoma: a prospective study.

Authors:  Yeonjung Ha; Tae Hun Kim; Jae Eul Shim; Sunghyun Yoon; Mi Jung Jun; Young-Ho Cho; Han Chu Lee
Journal:  Hepatol Int       Date:  2019-11-05       Impact factor: 6.047

2.  Comments on "Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer".

Authors:  Anshika Chauhan; Arnab Pal
Journal:  Br J Cancer       Date:  2022-04-12       Impact factor: 9.075

3.  Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer.

Authors:  Fei Tian; Shaohua Zhang; Chao Liu; Ziwei Han; Yuan Liu; Jinqi Deng; Yike Li; Xia Wu; Lili Cai; Lili Qin; Qinghua Chen; Yang Yuan; Yi Liu; Yulong Cong; Baoquan Ding; Zefei Jiang; Jiashu Sun
Journal:  Nat Commun       Date:  2021-05-05       Impact factor: 14.919

4.  Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer.

Authors:  Q Chen; L Yao; D Burner; B Minev; L Lu; M Wang; W Ma
Journal:  Clin Transl Oncol       Date:  2018-09-14       Impact factor: 3.340

5.  Establishment and Characterization of a CTC Cell Line from Peripheral Blood of Breast Cancer Patient.

Authors:  Pan Zhao; Wenbin Zhou; Chang Liu; Huirong Zhang; Zhiqiang Cheng; Weiqing Wu; Kaisheng Liu; Hong Hu; Caineng Zhong; Yayuan Zhang; Dongxian Zhou; Feiyuan Liu; Yong Dai; Jianhong Wang; Chang Zou
Journal:  J Cancer       Date:  2019-10-15       Impact factor: 4.207

6.  Biochemical phenotyping of multiple myeloma patients at diagnosis reveals a disorder of mitochondrial complexes I and II and a Hartnup-like disturbance as underlying conditions, also influencing different stages of the disease.

Authors:  Ismael Dale Cotrim Guerreiro da Silva; Erica Valadares de Castro Levatti; Amanda Paula Pedroso; Dirce Maria Lobo Marchioni; Antonio Augusto Ferreira Carioca; Gisele Wally Braga Colleoni
Journal:  Sci Rep       Date:  2020-12-14       Impact factor: 4.379

7.  Optimal Strategy for Colorectal Cancer Patients' Diagnosis Based on Circulating Tumor Cells and Circulating Tumor Endothelial Cells by Subtraction Enrichment and Immunostaining-Fluorescence In Situ Hybridization Combining with CEA and CA19-9.

Authors:  Shimu Luo; Yanghang Ou; Tingjin Zheng; Huihui Jiang; Yibo Wu; Jiangman Zhao; Zhishan Zhang
Journal:  J Oncol       Date:  2021-12-24       Impact factor: 4.375

8.  Inborn-like errors of metabolism are determinants of breast cancer risk, clinical response and survival: a study of human biochemical individuality.

Authors:  Ismael da Silva; Rene da Costa Vieira; Carolina Stella; Edson Loturco; André Lopes Carvalho; Carlos Veo; Cristovam Neto; Sandra M Silva; Paulo D'Amora; Marcia Salzgeber; Delcio Matos; Celso R Silva; Jose R Oliveira; Iara Rabelo; Patricia Yamakawa; Rui Maciel; Rosa Biscolla; Maria Chiamolera; Renato Fraietta; Felipe Reis; Marcelo Mori; Dirce Marchioni; Antonio Carioca; Gustavo Maciel; Renato Tomioka; Edmund Baracat; Clovis Silva; Celso Granato; Ricardo Diaz; Bruno Scarpellini; Daniel Egle; Heidi Fiegl; Irmgard Himmel; Christina Troi; Robert Nagourney
Journal:  Oncotarget       Date:  2018-08-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.